1. Compared to the 50-day high, the shares are 0.74 percent below this figure.
2. The shares are 21.15 percentage points away from its 50-day moving average and 16.51 percent away from its 200-day moving average, the Winfield Review reports.
3. Among analysts covering the stock, they have a 1.7 rating, with one indicating a “strong buy” and five indicating a “strong sell.”
4. The Street’s price target totals $21.20 for Surgery Partners shares.
5. Surgery Partners shares traded at $20.25 on Feb. 11, 2017.
More articles on surgery centers:
9 joint ventures ASC in January/ February
HSS, Stamford Health partner on ASC; Expect to have 400+ ambulatory cases by year’s end
Bay Area Regional Medical Center, Medistar team up on ASC — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
